Troriluzole

About Biohaven

Biohaven is a clinical-stage biopharmaceutical company with a mission to discover, develop, and commercialize life-changing therapies for severe diseases. Its most significant achievement was the discovery, approval, and subsequent $11.6 billion divestiture of its CGRP migraine franchise (Nurtec® ODT, Zavzpret®) to Pfizer in 2022, which provided substantial capital to fund its next-generation pipeline. The company's strategy is to leverage its proven drug development expertise and three proprietary technology platforms—glutamate modulation, myostatin inhibition, and Kv7 targeting—to build a diversified portfolio targeting large neurological and rare disease markets. Biohaven's 'patient-first' culture and non-hierarchical structure are designed to drive urgency and efficiency in clinical execution.

About Biohaven

Biohaven is a clinical-stage biopharmaceutical company with a mission to discover, develop, and commercialize life-changing therapies for severe diseases. Its most significant achievement was the discovery, approval, and subsequent $11.6 billion divestiture of its CGRP migraine franchise (Nurtec® ODT, Zavzpret®) to Pfizer in 2022, which provided substantial capital to fund its next-generation pipeline. The company's strategy is to leverage its proven drug development expertise and three proprietary technology platforms—glutamate modulation, myostatin inhibition, and Kv7 targeting—to build a diversified portfolio targeting large neurological and rare disease markets. Biohaven's 'patient-first' culture and non-hierarchical structure are designed to drive urgency and efficiency in clinical execution.

Therapeutic Areas

Other Spinocerebellar Ataxia (SCA) Drugs